Behavioral healthcare M&A pace picks up

The behavioral healthcare services space is gaining traction in the larger healthcare sector, and mergers and acquisition activity year to date reflects the growth, according to a new report from Capstone Headwaters.

Year to date, M&A activity in the subsector has already surpassed 2018 levels, with 38 recorded transactions, compared to 28 transactions YTD in 2018. The findings come at a time when M&A across the healthcare sector has continued to rise over the last several years, particularly among hospital and health systems.

Some of the driving factors ramping up M&A include a reduced stigma on mental illness, as well as the opioid abuse crisis across the nation. In particular, one 2018 bill, the Support for Patient and Communities Act, allotted $90 million in federal funding for opioid addiction.

Among the 38 transactions, outpatient services are becoming increasingly popular, with 18 companies offering outpatient care and 10 with a focus on child behavioral services. Still, outpatient services currently only represent 28% of behavioral services. Nearly 15% of adults received care, 7.5% of which received outpatient services and only 1% received inpatient services.

Capstone Headwaters is an investment bank focused on middle-market business owners, investors and creditors, providing advisory services for M&A, private placement and corporate restructuring.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.